uniQure N.V. - Special Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to today's top line data from HOPE-B pivotal trial of EtranaDez in hemophilia B. (Operator Instructions) I would also -- I also need to advise you that this conference is recorded today.
Without any further delay, I would now like to hand the conference over to Maria Cantor. Please go ahead.
Good afternoon, and thank you for joining us as we review the initial clinical data from the HOPE-B pivotal study of EtranaDez AMT-061 being studied in adult patients with severe and moderately severe hemophilia B. These data were highlighted today in a late-breaker oral presentation featured at the virtual ASH Annual Meeting.
Joining me for this event are Matt Kapusta, our Chief Executive Officer at uniQure; Dr. Ricardo Dolmetsch, our President of Research and Development; Eileen Sawyer, our Vice President of Global Medical Affairs; and Dr. Steven Pipe, Professor of Pediatrics and Pathology and the Pediatric Medical Director of the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |